"label","name","uuid:ID","text","id","description","instanceType"
"","OBJ1","2ae58e94-e8aa-4802-9185-946e7fca3089","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","Objective_1","Main objective","Objective"
"","OBJ2","dd03f0b5-5971-4f7b-8fff-7e09788f61a0","To document the safety profile of the xanomeline TTS.","Objective_2","Safety","Objective"
"","OBJ3","8a17367f-3e9a-4a40-91bc-019c2de08ede","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","Objective_3","Behaviour","Objective"
"","OBJ4","60a00d29-cada-4284-bef5-68e73681feae","To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).","Objective_4","","Objective"
"","OBJ5","ff85ac49-1ffb-49a1-98dc-fd0e014680ba","To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).","Objective_5","","Objective"
"","OBJ6","98afdacf-90a7-4927-8137-368eef035ab5","To assess the treatment response as a function of Apo E genotype.","Objective_6","","Objective"
